PF-06260933
PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
Product Specifications
CAS Number
1811510-56-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
MAP4K
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/PF-06260933.html
Concentration
10mM
Purity
99.39
Solubility
DMSO : 30 mg/mL (ultrasonic; warming)
Smiles
NC1=C(C2=CC=C(Cl)C=C2)C=C(C(C=N3)=CC=C3N)C=N1
Molecular Formula
C16H13ClN4
Molecular Weight
296.75
Precautions
H302, H315, H319, H335
References & Citations
[1]Ammirati M, et al. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Med Chem Lett. 2015 Oct 6;6 (11) :1128-33.|[2]Roth Flach RJ, et al. Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis. Nat Commun. 2015 Dec 21;6:8995.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MAP4K4/HGK
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400977-100 1x 100 µL
TGF-beta (1D11.16.8), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC812748-100 1x 100 µL
AMACR / p504S (Prostate Cancer Marker) (AMACR/2748R), CF680R conjugate, 0.1mg/mL
Sign In for Pricing
View Details